GeoVax Labs, Inc. (Nasdaq: GOVX) has highlighted 2026 as a pivotal inflection year for the company, driven by multiple late-stage clinical, regulatory, and manufacturing milestones across its diversified portfolio. The announcement follows the J.P. Morgan Healthcare Conference Week in San Francisco, where the company engaged with investors, bankers, and partners.
David Dodd, Chairman & CEO of GeoVax, stated, 'GeoVax enters 2026 with increasing clarity on execution, prioritization, and value creation. With GEO-MVA representing an expedited path to potential commercialization, alongside multiple clinical data readouts relative to GEO-CM04S1 and the anticipated initiation of the Phase 2 Gedeptin trial, we believe that this year will provide a meaningful convergence of regulatory, clinical, and manufacturing catalysts.'
GEO-MVA, the company's most advanced program targeting mpox and smallpox, is positioned for near-term commercialization. The global vaccine market remains constrained by reliance on a single foreign manufacturer, creating a structural supply imbalance. Following supportive Scientific Advice from the European Medicines Agency (EMA), GeoVax has regulatory alignment on a single, pivotal Phase 3 immunobridging study versus the approved MVA vaccine. Key 2026 milestones include initiation of the Phase 3 trial in the second half of the year and continued engagement with European and global health authorities.
In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy. Expected milestones include publication of results from a recently completed trial and initiation of a Phase 2 study evaluating Gedeptin in combination with an immune checkpoint inhibitor for head and neck cancer by year-end. The company is pursuing a partnership-oriented development strategy to preserve long-term upside.
For GEO-CM04S1, a next-generation COVID-19 vaccine, GeoVax expects clinical data readouts from ongoing Phase 2 trials and continued evaluation in immunocompromised populations. The vaccine is designed to address unmet needs inadequately served by current single-antigen vaccines.
The AGE1 continuous avian cell-line manufacturing process is directly integrated into the GEO-MVA program, offering a scalable alternative to traditional methods. Progress anticipated in 2026 includes continued optimization to support commercial-scale production and advancement as a U.S.-based manufacturing solution aligned with pandemic preparedness.
Dodd concluded, 'As we move through 2026, GeoVax is entering a phase where years of platform development, regulatory engagement, and manufacturing investment begin to translate into tangible outcomes. With GEO-MVA advancing along a clearly defined path toward commercialization, multiple clinical data readouts expected, and a scalable manufacturing foundation in place, we believe GeoVax is well positioned for a pivotal year of execution and value creation.'
For more information, visit GeoVax's website.
